Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus SULMEPRIM PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus SULMEPRIM PEDIATRIC.
ILOSONE SULFA vs SULMEPRIM PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, blocking folate reduction; sequential blockade leads to bactericidal effect.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
For Pneumocystis jirovecii pneumonia (PCP): 15-20 mg/kg/day (based on trimethoprim component) intravenously divided every 6-8 hours for 14-21 days. For other infections: 8-10 mg/kg/day (trimethoprim) orally or intravenously divided every 12 hours.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
Terminal elimination half-life: Sulfamethoxazole 9–12 hours, Trimethoprim 8–11 hours; prolonged in renal impairment (creatinine clearance <15 mL/min) requiring dose adjustment.
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Renal excretion accounts for approximately 70% (as unchanged sulfamethoxazole and trimethoprim) and 20% as metabolites; biliary/fecal elimination is minor at <10%.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic